The development of coronary artery disease (CAD) and myocardial infarction (MI) in the absence of SMuRFs (“SMuRFless”) has been highlighted as an area of unmet clinical need. It is believed to account for between 10-27 percent of ST elevation MI and associated with higher 30-day mortality.
This has sparked global interest, demonstrated by a rapid rise in publications in leading international journals.
The inaugural SMuRFless CAD Symposium will include global clinical and scientific leaders with presentations and facilitated discussions on:
Clinical characteristics and outcomes;
Unmet needs in early detection and treatments; and
Drug translation and evidence building
Register your attendance using the link below by 14 August 2023.
Thank you to our generous sponsors.